Headline News

 

FDA advisory committee votes against camizestrant combination for ESR1-mutant advanced breast cancer in a setback for AstraZeneca

Posted on May 05, 2026

FDA advisory committee backs AstraZeneca’s Truqap combination for PTEN-deficient metastatic hormone-sensitive prostate cancer

Posted on May 05, 2026

Pfizer secures three patent settlements for Vyndamax, extending exclusivity to mid-2031

Posted on May 05, 2026

Pfizer’s Elrexfio significantly improves progression-free survival in relapsed or refractory multiple myeloma

Posted on May 05, 2026

Lilly’s Omvoh delivers first ever four-year disease clearance data for an IL-23p19 therapy in ulcerative colitis

Posted on May 05, 2026

AstraZeneca’s Breztri approved in the US for asthma, becoming the first and only single-inhaler triple therapy for patients aged 12 and older

Posted on April 28, 2026

Sanofi’s Tzield approved in the US to delay onset of stage 3 type 1 diabetes in young children

Posted on April 28, 2026

Sanofi’s Cenrifki recommended for EU approval to treat non-relapsing secondary progressive multiple sclerosis

Posted on April 28, 2026

GSK’s TESARO provides update on AnaptysBio litigation

Posted on April 28, 2026

GSK’s efimosfermin receives FDA breakthrough therapy and EMA priority medicines designations for MASH

Posted on April 28, 2026

GSK’s bepirovirsen granted priority review and breakthrough therapy designation by FDA for chronic hepatitis B

Posted on April 28, 2026

AbbVie selects Durham, North Carolina for its largest ever manufacturing campus

Posted on April 28, 2026

Dupixent approved as first biologic for young children with uncontrolled chronic spontaneous urticaria

Posted on April 28, 2026

FDA approves Otarmeni the first gene therapy for genetic hearing loss as Regeneron commits to offering it for free

Posted on April 28, 2026

Regeneron strikes deal with white house to cut drug prices, offers gene therapy for free

Posted on April 28, 2026